MedTrace Logo

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

NCT06008119 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label, Phase 3 study

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Tunlametinib plus Vemurafenib

12mg BID Tunlametinib+720mg BID Vemurafenib

DRUG

Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

According to investigators' suggestion

Sponsors & Collaborators

  • Shanghai Kechow Pharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2026-12-24
Completion
2026-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06008119 on ClinicalTrials.gov